Showing results (301-310 of 4,868) with videos related to

Sort By:
Pageof 487
Urologic Oncology|August 11, 2022
The role of enhanced recovery after surgery protocols in the development of acute kidney injury following radical cystectomyZaeem Lone, Ao Zhang, Tarik Benidir, et al.
Urologic Oncology|June 16, 2020
Prospective development of a prostate cancer risk calculator in a racially diverse population: The Kaiser Permanente Prostate Cancer Risk CalculatorJoseph Presti, Stacey Alexeeff, Brandon Horton, et al.
Urologic Oncology|April 11, 2020
Concomitant carcinoma in situ as a prognostic factor in the upper tract urothelial carcinoma after radical nephroureterectomy: A systematic review and meta-analysisXiaoshuai Gao, Yucheng Ma, Guo Chen, et al.
Urologic Oncology|May 26, 2021
Papillary renal cell carcinoma: ReviewNeil Mendhiratta, Peter Muraki, Anthony E Sisk, et al.
Urologic Oncology|May 23, 2015
Influence of pathological factors on oncological outcomes after robot-assisted radical prostatectomy for localized prostate cancer: Results of a prospective studySébastien Kozal, Benoit Peyronnet, Susanna Cattarino, et al.
Urologic Oncology|June 14, 2015
Gonadotropin-releasing hormone antagonist: A real advantage?Takahiro Kimura, Hiroshi Sasaki, Kouhei Akazawa, et al.
Urologic Oncology|May 10, 2015
Quality of life and symptom assessment in randomized clinical trials of bladder cancer: A systematic reviewMichael A Feuerstein, Marc Jacobs, Alfonso Piciocchi, et al.
Urologic Oncology|May 12, 2015
Heterogeneity in D'Amico classification-based low-risk prostate cancer: Differences in upgrading and upstaging according to active surveillance eligibilityJonas Schiffmann, Philipp Wenzel, Georg Salomon, et al.
Urologic Oncology|May 5, 2015
Commentary on: "Randomized phase III trial of temsirolimus and bevacizumab versus interferon alfa and bevacizumab in metastatic renal cell carcinoma: INTORACT trial." Rini BI, Bellmunt J, Clancy J, Wang K, Niethammer AG, Hariharan S, Escudier B. Brian I. Rini, Cleveland Clinic Taussig Cancer Institute, Cleveland, OH; Joaquim Bellmunt, University Hospital del Mar-IMIM, Barcelona, Spain; Jill Clancy, Kongming Wang, Andreas G. Niethammer, Subramanian Hariharan, Pfizer, New York, NY; and Bernard Escudier, Institut Gustave Roussy, Villejuif, France.: J Clin Oncol. 2014 Mar 10;32(8):752-9; doi: 10.1200/JCO.2013.50.5305. [Epub 2013 Dec 2]Donald Trump
Urologic Oncology|May 5, 2015
Commentary on: "Randomized, controlled, double-blind, cross-over trial assessing treatment preference for pazopanib versus sunitinib in patients with metastatic renal cell carcinoma: PISCES study." Escudier B, Porta C, Bono P, Powles T, Eisen T, Sternberg CN, Gschwend JE, De Giorgi U, Parikh O, Hawkins R, Sevin E, Négrier S, Khan S, Diaz J, Redhu S, Mehmud F, Cella D. Bernard Escudier, Institut Gustave Roussy, Villejuif; Emmanuel Sevin, Centre François Baclesse, Caen; Sylvie Négrier, Leon Berard Cancer Center, Lyon, France; Camillo Porta, Fondazione Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Policlinico S. Matteo, Pavia; Cora N Sternberg, San Camillo Forlanini Hospital, Rome; Ugo De Giorgi, IRCCS Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori, Meldola, Italy; Petri Bono, Helsinki University Central Hospital, Helsinki, Finland; Thomas Powles, Barts Experimental Cancer Medicine Centre, Barts Cancer Institute, Queen Mary University of London, London; Tim Eisen, Cambridge University Health Partners, Cambridge; Omi Parikh, Royal Preston Hospital, Lancashire; Robert Hawkins, Christie Cancer Research UK, Manchester; Sadya Khan, Jose Diaz, and Faisal Mehmud, GlaxoSmithKline, Uxbridge, United Kingdom; Jürgen E Gschwend, Klinikum Rechts der Isar der Technischen Universität München, Munich, Germany; Suman Redhu, GlaxoSmithKline, Collegeville, PA; David Cella, Northwestern University Feinberg School of Medicine, Chicago, IL.: J Clin Oncol. 2014 May 10;32(14):1412-1418; doi: 10.1200/JCO.2013.50.8267. [Epub 2014 Mar 31]Donald Trump
Pageof 487